 |
|
| Blog results | Results 1 - 10 of about 5,438 for raloxifene trial. (0.25 seconds) |
| Sorted by relevance Sort by date |
| 20 Nov 2009 by admin In a recent, double-blinded, randomized, parallel trial of 390 healthy postmenopausal women, raloxifene in doses of 60 or 120 mg/d was compared to HRT (conjugated estrogens 0.625 mg and medroxyprogesterone 2.5 mg/d) or placebo to ... No SubHealth - http://www.nosubhealth.com/ |
| 29 Oct 2009 by Legault, Maki, Resnick, Coker, Hogan, Bevers,... The 1498 women who were randomly assigned in STAR were age 65 years and older, were not diagnosed with dementia, and were enrolled onto the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) trial, beginning 18 months after ... Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/ [ More results from Journal of Clinical Oncology Current Issue ] |
| 16 Nov 2009 by salud equitativa Osteosarcoma was reported in only one study, a head-to-head trial of raloxifene vs. tamoxifen; differences between groups were not significant. There are no data from osteoporosis trials that describe an association between ... CIENCIASMEDICASNEWS - http://elbiruniblogspotcom.blogspot.com/ - References [ More results from CIENCIASMEDICASNEWS ] |
| 19 Nov 2009 by Nelson HD, Fu R, Griffin JC, Nygren P,... Purpose: To summarize benefits and harms of tamoxifen citrate, raloxifene, and tibolone to reduce the risk for primary breast cancer. Data Sources: MEDLINE and Cochrane databases from inception to January 2009, Web of Science, trial ... JournalFeeds - http://journalfeeds.com/ |
| 17 Nov 2009 ... breast cancer compared with placebo: tamoxifen (risk ratio, 0.70; 95% CI, 0.59 to 0.82; 4 trials), raloxifene (risk ratio, 0.44; 95% CI, 0.27 to 0.71; 2 trials), and tibolone (risk ratio, 0.32; 95% CI, 0.13 to 0.80; 1 trial). ... NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/ [ More results from NeLM - News ] |
| 16 Nov 2009 by David Gorski Indeed, raloxifene, another SERM, is used primarily to prevent and treat bone loss in women with osteoporosis. A $110 million clinical trial showed that its ability to prevent breast cancer is not statistically significantly different ... Science-Based Medicine - http://www.sciencebasedmedicine.org/ - References |
| 10 Nov 2009 by VeZİRH@N In the MORE (Multiple Outcomes of Raloxifene Evaluation) trial, which randomised 7705 osteoporotic, postmenopausal women to 3 years of raloxifene 60 mg bid, 60 mg od, or placebo, the incidence of invasive breast cancer was 76% lower in ... Untitled - http://www.birdunyabilgi.net/ |
| 9 Feb 2009 by Collins, P., Mosca, L., Geiger, MJ, Grady,... Background—The Raloxifene Use for The Heart (RUTH) trial showed that raloxifene, a selective estrogen receptor modulator, had no overall effect on the incidence of coronary events in women with established coronary heart disease or ... Circulation recent issues - http://circ.ahajournals.org/ [ More results from Circulation recent issues ] |
| 16 Oct 2009 by geaHouse buy Evista (Raloxifene) online in United Kingdom * order Evista overnight cod Take Evista Pills * Evista (Raloxifene) free trial Evista (Raloxifene) pharmacy * Evista fed ex buy Evista (Raloxifene) now * Evista COD next day ... Gears of War Forum l Gears of War Videos... - http://gearsofwarforum.net/forum/ [ More results from Gears of War Forum l Gears of War Videos... ] |
| 16 Nov 2009 by richardkearns Then, in 1999, he had a chance to do another breast cancer prevention trial, this time of an osteoporosis drug, raloxifene, or Evista, which did not have the cancer drug taint. It was to be compared with tamoxifen. ... HIV/AIDS volunteer virtual assisted care... - http://havvacc.wordpress.com/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
